1. Signaling Pathways
  2. Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  3. ROR
  4. RORβ Isoform

RORβ

RORβ (retinoic acid receptor-related orphan receptor beta; RORB) is a member of the NR1 family of nuclear receptors and functions as a DNA-binding transcription factor that regulates gene expression through hormone response elements[1]. RORβ is highly enriched in the central nervous system, particularly in the cerebral cortex, retina, pineal gland, and suprachiasmatic nucleus, linking its transcriptional activity to neuronal differentiation, sensory circuit organization, retinal development, and circadian rhythm regulation[2][3][4]. Mechanistically, RORβ contributes to the establishment of cortical layer 4 identity and the development of specialized neuronal architectures, indicating a central role in neural circuit formation and maturation[3][5]. Experimental studies further demonstrate that disruption of Rorb alters circadian behavior and causes retinal degeneration, establishing valuable animal models for investigating neurodevelopmental and neurophysiological processes[6]. In disease-relevant contexts, aberrant circadian regulation mediated by RORβ has been discussed in relation to tumorigenesis and disease progression, while RORβ-dependent transcriptional programs remain an active area of mechanistic investigation[4]. Compared with the related isoforms RORα and RORγ, RORβ displays a more restricted expression pattern that is largely confined to the brain and retina, supporting distinct functions in neural and sensory systems rather than the broader metabolic or immune activities associated with other ROR family members[7]. For experimental applications, all-trans retinoic acid has been identified as a ligand that modulates RORβ transcriptional activity, providing a useful pharmacological tool for studying RORβ-regulated signaling pathways and target genes[8].

RORβ Related Products (1):

Cat. No. Product Name Effect Purity
  • HY-136527
    BMS-986251
    Antagonist
    BMS-986251 is an orally active and selective RORγt inverse agonist with an EC50 of 12 nM for RORγt GAL4. BMS-986251 inhibits IL-17 with an EC50 of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced (HY-B0180) models (preclinical models of psoriasis).